CA2200541C - Utilisation d'antagonistes de la lh-rh dans le traitement des troubles de l'infertilite - Google Patents

Utilisation d'antagonistes de la lh-rh dans le traitement des troubles de l'infertilite Download PDF

Info

Publication number: CA2200541C
Authority: CA; Canada
Prior art keywords: antagonist; lhrh; cetrorelix; day; treatment
Prior art date: 1997-01-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2200541A

Other languages

English (en)

Other versions

CA2200541A1 (fr

Inventor

Philippe Bouchard

Rene Frydman

Paul Devroey

Klaus Diedrich

Jurgen Engel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zentaris IVF GmbH

Original Assignee

Zentaris IVF GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-22

Filing date

1997-03-20

Publication date

2013-02-19

1997-03-20 Application filed by Zentaris IVF GmbH filed Critical Zentaris IVF GmbH

1998-07-22 Publication of CA2200541A1 publication Critical patent/CA2200541A1/fr

2013-02-19 Application granted granted Critical

2013-02-19 Publication of CA2200541C publication Critical patent/CA2200541C/fr

2017-03-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims description 18
208000021267 infertility disease Diseases 0.000 title abstract description 5
238000011282 treatment Methods 0.000 title description 23
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims abstract description 18
229960003230 cetrorelix Drugs 0.000 claims abstract description 18
108700008462 cetrorelix Proteins 0.000 claims abstract description 17
239000002474 gonadorelin antagonist Substances 0.000 claims abstract description 15
238000000034 method Methods 0.000 claims abstract description 13
239000002622 gonadotropin Substances 0.000 claims abstract description 11
230000000638 stimulation Effects 0.000 claims abstract description 11
102000006771 Gonadotropins Human genes 0.000 claims abstract description 10
108010086677 Gonadotropins Proteins 0.000 claims abstract description 10
210000000287 oocyte Anatomy 0.000 claims description 8
230000003325 follicular Effects 0.000 claims description 7
230000002611 ovarian Effects 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 6
-1 Azaline B Chemical compound 0.000 claims description 4
NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 3
WDYSQADGBBEGRQ-APSDYLPASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2r,3r,4r,5r,6s) Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WDYSQADGBBEGRQ-APSDYLPASA-N 0.000 claims description 3
VSZVSSYQFUFEQG-GJZGRUSLSA-N (2s)-5-amino-2-[[(2s)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-5-oxopentanoic acid Chemical compound C1=CC=CC2=CC(C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CC=C21 VSZVSSYQFUFEQG-GJZGRUSLSA-N 0.000 claims description 3
108010082661 2-naphthylalanyl-glutamic acid Proteins 0.000 claims description 3
108010070670 antarelix Proteins 0.000 claims description 3
229940127233 azaline B Drugs 0.000 claims description 3
GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 3
108700032141 ganirelix Proteins 0.000 claims description 3
229960003794 ganirelix Drugs 0.000 claims description 3
108010092834 ramorelix Proteins 0.000 claims description 3
229950000277 ramorelix Drugs 0.000 claims description 3
238000010254 subcutaneous injection Methods 0.000 claims description 3
239000007929 subcutaneous injection Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims 3
239000000203 mixture Substances 0.000 claims 3
108010031335 A 76154 Proteins 0.000 claims 2
239000002552 dosage form Substances 0.000 claims 2
108010083551 iturelix Proteins 0.000 claims 2
QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims 2
OVJXZVMFCYBEPE-RWRBTDCVSA-N n-[(5r)-5-amino-6-[[(2s)-1-[[(2r)-2-[[(2s)-1-[(2s)-2-amino-6-(propan-2-ylamino)hexanoyl]pyrrolidine-2-carbonyl]-[(2s)-2-[[(2r)-2-[3-(4-fluorophenyl)propanoylamino]-3-naphthalen-1-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]-[(2s)-3-(4-hydroxyphe Chemical compound C([C@H](NC)C(=O)N(C(=O)[C@@H](C)N(C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2C=CC=1)NC(=O)CCC=1C=CC(F)=CC=1)C(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCCNC(C)C)C(=O)[C@H](CC(C)C)NC(=O)[C@H](N)CCCCNC(=O)C=1C=NC=CC=1)C1=CC=C(O)C=C1 OVJXZVMFCYBEPE-RWRBTDCVSA-N 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 12
230000016087 ovulation Effects 0.000 abstract description 10
230000009977 dual effect Effects 0.000 abstract description 7
239000000556 agonist Substances 0.000 abstract description 5
238000011161 development Methods 0.000 abstract description 5
230000018109 developmental process Effects 0.000 abstract description 5
230000001629 suppression Effects 0.000 abstract description 5
229940011871 estrogen Drugs 0.000 abstract description 4
239000000262 estrogen Substances 0.000 abstract description 4
230000028327 secretion Effects 0.000 abstract description 3
230000001939 inductive effect Effects 0.000 abstract description 2
230000029849 luteinization Effects 0.000 abstract description 2
208000011580 syndromic disease Diseases 0.000 abstract description 2
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 abstract 6
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 6
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 6
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 6
230000005906 menstruation Effects 0.000 abstract 1
230000003472 neutralizing effect Effects 0.000 abstract 1
238000007920 subcutaneous administration Methods 0.000 abstract 1
108010073521 Luteinizing Hormone Proteins 0.000 description 13
102000009151 Luteinizing Hormone Human genes 0.000 description 13
229940040129 luteinizing hormone Drugs 0.000 description 13
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
230000002028 premature Effects 0.000 description 11
108010057021 Menotropins Proteins 0.000 description 8
230000035935 pregnancy Effects 0.000 description 7
230000004720 fertilization Effects 0.000 description 6
230000008217 follicular development Effects 0.000 description 5
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 5
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 4
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 4
102100024028 Progonadoliberin-1 Human genes 0.000 description 4
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 4
229940094892 gonadotropins Drugs 0.000 description 4
230000001817 pituitary effect Effects 0.000 description 4
230000001270 agonistic effect Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000027758 ovulation cycle Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
208000007984 Female Infertility Diseases 0.000 description 2
206010021928 Infertility female Diseases 0.000 description 2
208000007466 Male Infertility Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
206010042573 Superovulation Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
239000002434 gonadorelin derivative Substances 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
230000035800 maturation Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000011277 treatment modality Methods 0.000 description 2
206010048010 Withdrawal syndrome Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000037416 cystogenesis Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
208000025661 ovarian cyst Diseases 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
238000009521 phase II clinical trial Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2200541A 1997-01-22 1997-03-20 Utilisation d'antagonistes de la lh-rh dans le traitement des troubles de l'infertilite Expired - Lifetime CA2200541C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US78693797A	1997-01-22	1997-01-22
US08/786,937		1997-01-22

Publications (2)

Publication Number	Publication Date
CA2200541A1 CA2200541A1 (fr)	1998-07-22
CA2200541C true CA2200541C (fr)	2013-02-19

Family

ID=25139990

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2200541A Expired - Lifetime CA2200541C (fr)	1997-01-22	1997-03-20	Utilisation d'antagonistes de la lh-rh dans le traitement des troubles de l'infertilite

Country Status (1)

Country	Link
CA (1)	CA2200541C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8173592B1 (en) *	1999-03-31	2012-05-08	Zentaris Ivf Gmbh	Method for a programmed controlled ovarian stimulation protocol
CN116350617A (zh) *	2023-03-03	2023-06-30	南京师范大学	Luf5771在制备预防和/或治疗卵巢过度刺激综合征的药物中的用途

1997
- 1997-03-20 CA CA2200541A patent/CA2200541C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2200541A1 (fr)	1998-07-22

Legal Events

Date	Code	Title	Description
2002-02-05	EEER	Examination request
2017-05-22	MKEX	Expiry	Effective date: 20170320

Publication	Publication Date	Title
Shoham et al.	1991	Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone
Diedrich et al.	1994	Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
US9107871B2 (en)	2015-08-18	LHRH—antagonists in the treatment of fertility disorders
Olivennes et al.	2002	The use of GnRH antagonists in ovarian stimulation
Coccia et al.	2004	GnRH antagonists
Felberbaum et al.	1999	Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists
Filicori et al.	1999	Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea
Charbonnel et al.	1987	Induction of ovulation in polycystic ovary syndrome with a combination of a luteinizing hormone-releasing hormone analog and exogenous gonadotropins
JP2005501918A (ja)	2005-01-20	制御下の過排卵刺激におけるｈＣＧの使用
RU2221588C2 (ru)	2004-01-20	Способ терапевтического лечения бесплодия
CA2367214C (fr)	2008-07-29	Technique pour protocole de stimulation ovarienne commandee, programmee
Marcus et al.	1993	Comparative trial between an ultra-short and long protocol of luteinizing hormone-releasing hormone agonist for ovarian stimulation in in-vitro fertilization
Roulier et al.	2003	Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
Chang et al.	1993	No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist
Zafeiriou et al.	2000	The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction
Herman et al.	1990	Follicle cysts after menstrual versus midluteal administration of gonadotropin-releasing hormone analog in in vitro fertilization
Howles	2002	The place of gonadotrophin-releasing hormone antagonists in reproductive medicine
US7815912B2 (en)	2010-10-19	Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
CA2200541C (fr)	2013-02-19	Utilisation d'antagonistes de la lh-rh dans le traitement des troubles de l'infertilite
Cassidenti et al.	1991	Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report
Lipitz et al.	1989	Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols
Zakaria et al.	2021	Assisted Conception: Preparing the Ovaries for Eggs Collection and Determination of the Outcome in Frozen Embryos Transfer (FET) During Natural Cycle IVF
CN1199642A (zh)	1998-11-25	治疗不育症的lhrh－拮抗剂
Grochowski et al.	1995	The results of an in vitro fertilization program: two regimens of superovulation
Check et al.	0	Effect of antagonists vs agonists on